CCR2 Inhibitor
-
DOTA-ECL1i
0 ImagesDOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.
-
Viscumneoside V
0 ImagesViscumneoside V is a plant-derived anti-inflammatory agent present in Viscum album var. coloratum. Viscumneoside V inhibits the expression of MCP-1 and promotes the production of RANTES in LPS-stimulated immune cells. Viscumneoside V can be used for research related to skin rashes.
-
Plozalizumab
0 ImagesSynonyms: MLN-1202Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
-
CCR2-IN-1
0 ImagesCat. No.: HY-402739CAS No.: 3088041-47-5CCR2-IN-1 (Compound HO11553-TM) is a G protein-coupled receptor CCR2 inhibitor. CCR2-IN-1 slows the progression of idiopathic pulmonary fibrosis. CCR2-IN-1 can be used for the research of idiopathic pulmonary fibrosis.
-
JNJ-41443532
0 ImagesSynonyms: CCR2 antagonist 5JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). JNJ-41443532 displays a Ki of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease.
-
ECL1i
0 ImagesCat. No.: HY-P11553CAS No.: 1417312-35-6ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis.
-
Propagermanium
0 ImagesCat. No.: HY-19009BCAS No.: 126595-07-1Propagermanium is an orally active and selective CCR2 inhibitor. Propagermanium enhances IFN-γ, IL-2, 2',5'-oligoadenylate synthetase, and unspecified cytokine production, and induces mature cytolytic NK cell subsets. Propagermanium reduces HBe antigen and HBV DNA polymerase levels, promotes HBV clearance and lowers serum ALT. Propagermanium downregulates STAT1, inhibits pro-inflammatory microglia polarization, pro-inflammatory cytokine release, and monocyte/macrophage infiltration. Propagermanium can be used for the research of chronic hepatitis B, atherosclerosis, breast cancer, non-alcoholic steatohepatitis, insulin resistance, refractory gastric cancer, multiple myeloma, type 2 diabetes.
-
Emapticap pegol scramble negative control
0 ImagesCat. No.: HY-148100CEmapticap pegol scramble negative control, an oligonucleotide aptamer, is the negative control of Emapticap pegol (HY-148100).
